This artificial intelligence detects brain tumor during surgery in 10 seconds

Scientists model a new artificial intelligence to help Treatment of brain cancer have developed that during surgery it can include other resectable parts of the tumor 10 seconds to diagnose

Technology developed by scientists from the University of Michigan and the University of California FastGlioma It’s called and they say it uses conventional methods to identify residual tumor parts during surgery. Todd Hallon, a neurosurgeon at the University of Michigan and the principal investigator of the study, says:

“FastGlioma is an artificial intelligence-based diagnostic system that has the potential to change the field of neurosurgery by immediately improving the comprehensive management of patients with diffuse glioma (a type of brain cancer). “This technology works faster and more accurately than the current standard methods in terms of tumor diagnosis and can be used in the diagnosis of other brain tumors in children and adults.”

Accuracy of FastGlioma in brain tumor diagnosis

To develop this AI-based model, neurosurgery teams analyzed fresh, unprocessed samples from 220 glioma patients. In their study, published in the journal Nature, they claimed that FastGlioma was able to detect and quantify residual tumors with an average accuracy of approximately 92%.

Also about the performance of FastGlioma, it is claimed that this artificial intelligence technology failed to detect high-risk tumors only 3.8% of the time, while this rate is approximately 25% for current routine methods.

FastGlioma uses microscopic optical imaging systems combined with artificial intelligence developed with training data to detect residual brain tumor.

Ultimately, the scientists claim that the technology, in addition to being an accessible and cost-effective tool for neurosurgery teams working on glioma, can also accurately detect residual fragments in non-glioma tumors, including pediatric brain tumors such as medulloblastoma. They also plan to focus on detecting other cancers in the future, including lung, prostate and breast cancer with FastGlioma.